|
|
|
| home > news > detailed info |
|
|
 INDUSTRY NEWS AND PRESS RELEASES |
Schrödinger Announces Acquisition of XTAL BioStructures, Inc. |
 |
|
NEW YORK--(BUSINESS WIRE)--Jan. 18, 2022-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the acquisition of XTAL BioStructures, Inc., a private company based in the Greater Boston area that provides structural biology services, including biophysical methods, protein production and purification, and X-ray crystallography, to the pharmaceutical and biotechnology industries.
The acquisition of XTAL BioStructures enables Schrödinger to pursue scientific advancements in the field of structural biology, augment its ability to produce high quality target structures for its drug discovery programmes, and expand its offerings to include an advanced and differentiated service that provides customers access to protein structures that have been computationally validated and are ready for structure-based virtual screening and lead optimisation.
“The acquisition of XTAL BioStructures enables us to continue to meaningfully advance the field of structure-based drug discovery. Through the integration of experimental and computational approaches, we can continue to improve techniques to prepare proteins for structure-based drug design methods,” said Ramy Farid, Ph.D., chief executive officer at Schrödinger. “Because high quality protein structures are core to our business, we wanted to bring these experimental capabilities in-house. With this acquisition, we will have access to more structures, and will leverage our protein structure refinement methods to scale up production of high-resolution structures, which are starting points for our physics-based computational platform.”
“XTAL and Schrödinger share a strong cultural fit and commitment to science, which was a very important consideration for both organisations,” said Robert Suto, Ph.D., chief executive officer at XTAL BioStructures. “We are excited to join forces and look forward to Schrödinger’s investment in our capabilities.”
Schrödinger and XTAL BioStructures closed the $6 million all-cash acquisition on January 14, 2022, and XTAL BioStructures is now operating as part of Schrödinger. XTAL is headquartered in Natick, Massachusetts with 18 employees, and Schrödinger will continue to operate XTAL BioStructures’ services at the current location.
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
airea - The Airport Region in Central Germany
Leipzig/Halle Airport joins forces to attract investors - the aiport and development agencies sign a cooperation agreement covering more than one federal state.
More info >> |
|
 |
White Papers |
 |
|
Novo Nordisk Pharmatech A/S signs distribution agreement with DKSH for twelve countries in Asia Pacific.
Novo Nordisk Pharmatech A/S
Novo Nordisk Pharmatech A/S and DKSH, have partnered to provide high-quality cGMP quaternary ammonium compounds in twelve countries across Asia Pacific.
More info >> |
|
 |
Industry Events |
 |
Pharmaceutical Manufacturing & Packaging Congress (PHARMAP 2022)
20-21 June 2022, Berlin, Germany
Pharmaceutical Manufacturing & Packaging Congress (PHARMAP 2022) is
held on June, 20-21, 2022 in Berlin, Germany. The Congress gathers
pharmaceutical companies, CMOs and CDMOs, governmental bodies together
with pharmaceutical equipment providers and service companies to discuss
the manufacturing and packaging processes of the pharmaceutical
industry. Among the participating companies are Bayer, Sandoz, Merck,
Novartis, Roche, Genveon, Samsung Biologics, Pfizer.
More info >> |
|
|
